(Q43295185)

18 November 2017

title

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? (English)

1 reference

18 November 2017

A Bar-Or

1

1 reference

18 November 2017

J Oger

2

1 reference

18 November 2017

E Gibbs

3

1 reference

18 November 2017

M Niino

4

1 reference

18 November 2017

T Aziz

5

1 reference

18 November 2017

C Renoux

6

1 reference

18 November 2017

S Alatab

7

1 reference

18 November 2017

F D Shi

8

1 reference

18 November 2017

D Campagnolo

9

1 reference

18 November 2017

F Jalili

10

1 reference

18 November 2017

S Rhodes

11

1 reference

18 November 2017

T Yamashita

12

1 reference

18 November 2017

B Fan

13

1 reference

18 November 2017

M S Freedman

14

1 reference

18 November 2017

H Panitch

15

1 reference

18 November 2017

D L Arnold

16

1 reference

18 November 2017

T Vollmer

17

1 reference

18 November 2017

publication date

1 August 2009

1 reference

Multiple Sclerosis Journal

18 November 2017

published in

1 reference

18 November 2017

volume

15

1 reference

18 November 2017

issue

8

1 reference

18 November 2017

page(s)

959-964

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

The immunology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Human regulatory T cells and their role in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106230

21 January 2018

Identifiers

DOI

10.1177/1352458509106230

1 reference

18 November 2017

1 reference